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Conclusions: The proteomic and epigenetic characterisation of TAF revealed 
specific protein and miRNA expression patterns in comparison to non-tumour 
fibroblasts. We observed induced expression alterations on proteomic and 
epigenetic level by means of co-cultivation transwell assay with tumour cells and 
fibroblasts. The expression changes will be also analysed in a tumour-like spheroid 
cell culture model. The results of this study demonstrate a strong tumour specific 
interplay of tumour cells and fibroblasts.
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introduction & objectives: To assess core biopsy accuracy among Renal Cell 
Carcinomas (RCC) by comparing preoperative and postoperative histological 
subtype and Führmann nuclear grade. Management of small renal masses being 
related to these results, correlation between accuracy and tumour size was then 
evaluated.
Materials & Methods: At our institution, 77 patients underwent both core renal 
biopsy and then surgical resection for primary RCC between February 2004 
and February 2010. Percutaneous 18-gauge core biopsies were obtained under 
ultrasound or computed tomography guidance. According to tumour size, two 
groups were constituted (<4cm and ³4cm). Preoperative subtype and grade were 
compared with postoperative specimens results.
results: Mean tumour size was 35.8 mm (range 10-115). Overall, biopsy correctly 
identified 66 out of 77 (88.0%) histological subtypes ; 5 (6.5%) primary RCC 
subtypes could not be defined and 6 more biopsies showed normal parenchyma 
(7.8%). Führmann grade was accurately assigned for 47 out of 67 (61.0%) 
conclusive biopsies, underestimated for 14 (18.2%) and not defined for 10 (14.9%) 
(p<0.05). Pooled with unconclusive biopsies, not less than 19 of 22 (86.4%) high 
grade tumours were not diagnosed by the biopsy. Tumour size had no statistically 
significant influence on biopsy accuracy.
Conclusions: Core renal biopsy can accurately define RCC histologic subtype. 
However it doesn’t seem to be able to detect high grade tumours. Tumour size 
does not seem to influence these results.
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introduction & objectives: The aim of the study is to evaluate the usefulness of 
contrast-enhanced ultrasonography (CEUS) in characterization and follow-up of 
renal lesions.
Materials & Methods: From March to September 2010 we performed contrast 
enhanced ultrasonography (CEUS) in 29 patients to evaluate 42 renal lesions. We 
used SonoVue (Bracco) contrast agent, MyLab 70 Gold (Esaote) and Qontrast 
(AMID-Bracco) dedicated software for quantification of perfusions.
results: Overall, 37 (88%) lesions were evaluated with CEUS to better characterize 
previous CT scan with organojodate contrast agent (CECT) or to compare CT 
findings to the new method. In 4 patients with initial renal failure (5 lesions) CEUS 
was directly performed after standard ultrasonography (US): in this set of patients, 
the CEUS features were represented by suspected solid renal masses, so it was 
required a CECT evaluation. CEUS better defined the US features in all cases 
(p=0.001), in 20 cases (47.6%) it was adequate to characterized the lesions. In all 
these patients CECT confirmed CEUS findings. Overall, CEUS demonstrated a 
matching diagnosis with CECT in 38/42 (90.4%) lesions. In the remaining 4 cases, 
CT failed to show tumor blood flow in small lesions, while the CEUS capacity 
to quantify the perfusion demonstrated the presence of subcentrimetrical renal 
masses, discovered to be clear cell renal carcinoma histopathologically confirmed. 
Diagnostic value of CEUS resulted comparable to the CECT one, moreover 
CEUS was found to have an higher sensibility in characterizing small renal lesions 
(<1.5cm in greatest dimensions) or suspected cysts (BIIf, BIII) (p<0.0001). None of 
the patients has suffered adverse reactions to CEUS contrast agent, and no renal 
function worsening was suspected.
Conclusions: Contrast enhanced ultrasonography (CEUS) resulted more 
sensitive in detecting slight tumor blood flow than contrast enhanced CT with 
an improved characterization of small renal tumors. CEUS allowed a better 
visualization of septa number, septa and/or wall thickness, solid component and 
the enhancement of some renal cystic masses than standard CT. Moreover, the 
dedicated software (Qontrast) allowed a confirmation and a detailed definition of 
the observed features by the development of color maps and time-intensity curves. 
This safe, cost-effective procedure might be useful to better define renal lesions in 
patients undergoing to surgery, or to tailor an active surveillance of small masses 
or a postoperative follow-up avoiding organojodate contrast induced nephropathy.
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introduction & objectives: To our knowledge the impact of venous tumor 
thrombus (VTT) consistency in patients affected by renal cell carcinoma (RCC) 
has never been addressed.We analyzed the effect of VTT consistency on cancer-
specific mortality (CSM).
Materials & Methods: We retrospectively analyzed 174 consecutive patients with 
RCC and renal vein or inferior vena cava VTT, who underwent surgical treatment 
surgically treated between 1989 to 2007 at our Institute. All patients underwent 
radical nephrectomy and thrombectomy. Pathologic specimens were reviewed by a 
single uropathologist. In addition to traditional pathologic features, the morphologic 
aspect of the tumor thrombus was specifically evaluated to distinguish solid versus 
friable pattern. The prognostic role of thrombus consistency (solid vs friable) on 
CSM was assessed by means of Cox regression models.
results: The VTT was solid in 107 (61.5%) and friable in 67 (38.5%) patients. 
The presence of a friable VTT increased the risk of having synchronous nodal or 
distant metastases, higher tumor grade, higher pathologic stage, and simultaneous 
perinephric fat invasion (PFI) (all p < 0.05). The median follow-up was 24 months. 
The median CSM-free survival was 33 months. The median CSM-free survival in 
patients with a friable or a solid VTT was 8 and 55 months, respectively (p < 0.001). 
At multivariable analyses, the presence of a friable VTT was an independent 
predictor of CSM (p = 0.02). The power of our conclusion may be somewhat limited 
by the relative small study population and the retrospective nature of the study.
Conclusions: In patients with RCC and VTT, the presence of a friable thrombus 
is an independent predictor of CSM. If our finding is confirmed by further studies, 
the consistency of the tumor thrombus should be introduced into routine pathologic 
reports to provide better patient risk stratification.
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introduction & objectives: To validate the Karakiewicz nomogram using 
preoperative variables to predict cancer-specific survival of patients undergoing 
radical or partial nephrectomy for RCC.
Materials & Methods: We collected retrospectively the data of 3364 patients 
surgically treated for RCC in 16 academic centers involved in the Surveillance 
And Treatment Update Renal Neoplasms (SATURN) project. Univariable and 
multivariable Cox regression models addressed cancer-specific mortality. 
Concordance index was used to evaluate the prognostic accuracy of the nomogram 
12, 24, 60, and 120 months after surgery.
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results: All the variables included in the nomograms (age, gender, mode of 
presentation, clinical tumor size, clinical T stage, presence of metastasis) were 
independent predictor of CSS in multivariable analysis (all p values <0.02). The 
prognostic accuracy of the nomogram was 87.8% (IC95% 84.4-91.4) at 12-mo; 
87% (IC95% 84.4-89.5) at 24-mo; 84% (IC95% 82.3-87.1) at 60-mo; and 85.9% 
(IC95% 83.2-88.6) at 120-mo from surgery. Calibrations curve showed that the 
nomogram tended to significantly overestimate the rates of freedom from cancer-
specific mortality a 60 and 120-mo, whereas the differences between estimates 
and observed rates at 12- and 24-mo were limited.
Conclusions: Karakiewicz nomograms has a high prognostic accuracy both in 
short and long term evaluation of cancer-related outcome of patients with RCC. 
However, according to our series, the nomograms tend to underestimate the risk of 
cancer-specific deaths both 60 and 120-mo after surgery.
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introduction & objectives: Accurate prediction of cancer-specific survival in 
patients with renal cortical tumors (RCs) is important for counselling, planning 
of follow-up, and selection for appropriate adjuvant trial designs. We aimed to 
externally validate the most accurate nomogram available (J Clin Oncol 2007, 
25(11):1316-22) to predict cancer specific mortality (CSM) in RCC patients.
Materials & Methods: Clinical and pathologic data were prospectively gathered in 
1170 consecutive patients treated with radical nephrectomy or partial nephrectomy 
at a single Academic Center, between 1991 and 2010. Nomogram predicted 
survival probability and actual CSM were compared. Discrimination was quantified 
with the area under the receiver operating characteristics curve (AUC). Calibration 
compared the predicted and the observed cancer rates throughout the entire range 
of predictions.
results: At a median 89-month follow-up 256 renal cell carcinoma related deaths 
had occurred (21.9%). T classification according to TNM 2010 was pT1a, pT1b, 
pT2a, pT2b, pT3a, pT3b, pT3c and pT4 in 370 (31.6%), 347 (29.7%), 80 (6.8%), 
44 (3.8%), 234 (20.0%), 14 (1.2%), 49 (4.2%) and 32 (2.7%), respectively. Mean 
pathological diameter of the tumor was 6.1 cm (median 5.0 cm, range 1-23). 
At nephrectomy lymph node and distant metastases were present in 83 (7.1%) 
and 182 cases (15.6%), respectively. Grade 1-2 or 3-4 was noted in 824 tumors 
(70.4%) and 346 (29.5%), respectively. Thirty-seven (3.2%) and 80 (6.8%) patients 
showed local and systemic symptoms at diagnosis, respectively. One, 2, 5 and 
10-year cancer specific survival rates were 91.9%, 87.2%, 79.3% and 72.9%, 
respectively. For nomogram-derived CSM-free survival predictions at 1 to 10 years, 
the accuracy of the nomogram ranged from 85.5 to 91.1%. The calibration between 
the predicted and observed recurrence-free survival rates was virtually perfect at 
1 to 5 years after nephrectomy with slightly departures between the predicted and 
observed rates between 5 and 10 years after nephrectomy.
Conclusions: We externally validated a highly accurate tool specifically for 
renal renal cell carcinoma to predict disease specific survival. This nomogram 
resulted the most accurate tool to identify renal cell carcinoma with aggressive 
clinical behavior and may contribute to the ability to individualize postoperative 
surveillance and therapy.
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introduction & objectives: To compare the performances of UISS, SSIGN score, 
and Karakiewicz nomogram in a large multi-institutional series of patients with 
clear cell RCC.
Materials & Methods: We collected retrospectively the preoperative, pathological 
and follow-up data of 1871 patients treated in 16 academic centers. The predictive 
accuracy of the three prognostic models for prediction of CSS was quantified 
according to Harrell’s concordance index, whereas differences were estimated 
using the DeLong test. Decision curve analyses were used to determine the 
optimal benefit derived from the use of the 3 models.
results: At a median follow-up of 40 months, 272 (15%) had died of disease. 
Overall 3- and 5-year CSS estimates were 87.5% and 83.1%, respectively. The 
predictive accuracy estimates for prediction of CSS at 3 and 5 years were 88.9% 
and 88.8% for the Karakiewicz nomogram; 85.0%, and 84.1% for the UISS; and 
87.9% and 82.5% for the SSIGN score, respectively. Most of the differences in 
predictive accuracy were statistically significant. Calibration plots demonstrated 
substantial departures from ideal predictions for all the model. The Karakiewicz 
nomogram demonstrated the highest net benefit up to threshold probability of 25% 
and 37% at 3 and 5 yrs, respectively. Following those thresholds, the UISS resulted 
with the highest net benefits.
Conclusions: All three models demonstrated substantially sensible predictive 
accuracy, but all tend to underestimate the CSS probabilities. The Karakiewicz 
nomogram demonstrated the highest net benefit up to threshold probabilities of 
25% at 3 yr and 37% at 5 yr, whereas, the UISS resulted with the highest net 
benefit in patients with higher risks of deaths.
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introduction & objectives: Controversy exists in the management of elderly 
patients with RCC. Some reports suggest that in these patients, surgical treatment 
may actually cause harm, while others disagree. We sought to test this hypothesis 
in a large population-based North American cohort.
Materials & Methods: Between years 1988 and 2006, 36333 RCC patients treated 
with partial or radical nephrectomy (RN) were identified within the Surveillance, 
epidemiology and end results database. Patient age was stratified into decades: 
<50 vs. 50–59 vs. 60–69 vs. 70–79 vs. ≥80 years old. Disease stage was defined 
according to the AJCC/TNM staging system: stage I vs. stage II vs. stage III vs. 
stage IV. Tumor grade was defined low (I–II) vs. high (III–IV). Cox regression 
analyses were performed for prediction of CSM in the entire population, then 
repeated according to AJCC stage and grade categories. Finally, we repeated our 
analyses in patients treated with exclusively RN.
results: Respectively 18, 25, 27, 23, and 7% of patients were aged <50, 50–59, 
60–69, 70–79, and ≥80 years. Most patients were white (82%), underwent a RN 
(80%), clear cell (89%), low grade (74%), and stage I (67%). After adjusting to all 
covariates, persons aged ≥80 years had a higher rate of CSM than their younger 
counterparts (hazard ratio [HR]: 2.3, P<0.001). This effect was consistent in the 
stage per stage analysis: stage I HR: 5.1, P<0.001 vs. stage II HR: 2.0, P<0.001, 
stage III HR: 1.8, P<0.001, stage IV HR: 1.7, P<0.001. Following stratification of 
patients according to stage and grade categories, the effect of worse survival in 
octogenarians persisted across all categories. Furthermore, this finding remained 
unchanged in patients treated with exclusively RN.
Conclusions: More advanced age is an independent predictor of higher CSM 
across all stage and grade categories after nephrectomy. In consequence, surgical 
management of the elderly in RCC patients may not represent the ideal treatment 
option. Further studies are needed to confirm these results.
